Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 0.74
NVAX's Cash-to-Debt is ranked lower than
84% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NVAX: 0.74 )
Ranked among companies with meaningful Cash-to-Debt only.
NVAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07  Med: 7 Max: No Debt
Current: 0.74
Equity-to-Asset -0.01
NVAX's Equity-to-Asset is ranked lower than
92% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NVAX: -0.01 )
Ranked among companies with meaningful Equity-to-Asset only.
NVAX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.76 Max: 0.96
Current: -0.01
-0.01
0.96
Piotroski F-Score: 2
Altman Z-Score: -4.30
Beneish M-Score: -5.74
WACC vs ROIC
13.03%
-407.91%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -1752.84
NVAX's Operating Margin % is ranked lower than
82% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NVAX: -1752.84 )
Ranked among companies with meaningful Operating Margin % only.
NVAX' s Operating Margin % Range Over the Past 10 Years
Min: -11502.46  Med: -1093.3 Max: -134.38
Current: -1752.84
-11502.46
-134.38
Net Margin % -1823.53
NVAX's Net Margin % is ranked lower than
83% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NVAX: -1823.53 )
Ranked among companies with meaningful Net Margin % only.
NVAX' s Net Margin % Range Over the Past 10 Years
Min: -12414.15  Med: -1128.23 Max: -129.13
Current: -1823.53
-12414.15
-129.13
ROE % -221.33
NVAX's ROE % is ranked lower than
92% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NVAX: -221.33 )
Ranked among companies with meaningful ROE % only.
NVAX' s ROE % Range Over the Past 10 Years
Min: -195.01  Med: -49.82 Max: -34.3
Current: -221.33
-195.01
-34.3
ROA % -59.38
NVAX's ROA % is ranked lower than
72% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NVAX: -59.38 )
Ranked among companies with meaningful ROA % only.
NVAX' s ROA % Range Over the Past 10 Years
Min: -71.75  Med: -38.35 Max: -27.39
Current: -59.38
-71.75
-27.39
ROC (Joel Greenblatt) % -703.73
NVAX's ROC (Joel Greenblatt) % is ranked lower than
57% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NVAX: -703.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -736.29  Med: -469.42 Max: -247.56
Current: -703.73
-736.29
-247.56
3-Year Revenue Growth Rate -22.60
NVAX's 3-Year Revenue Growth Rate is ranked lower than
76% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NVAX: -22.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -57.7  Med: -2.25 Max: 247.6
Current: -22.6
-57.7
247.6
3-Year EBITDA Growth Rate 48.80
NVAX's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NVAX: 48.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -58.7  Med: -5.2 Max: 102.6
Current: 48.8
-58.7
102.6
3-Year EPS without NRI Growth Rate 49.20
NVAX's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NVAX: 49.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.1 Max: 52.3
Current: 49.2
0
52.3
GuruFocus has detected 3 Warning Signs with Novavax Inc $NVAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVAX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

NVAX Guru Trades in Q1 2016

George Soros 30,300 sh (New)
Steven Cohen Sold Out
» More
Q2 2016

NVAX Guru Trades in Q2 2016

Steven Cohen 180,000 sh (unchged)
George Soros Sold Out
» More
Q3 2016

NVAX Guru Trades in Q3 2016

Paul Tudor Jones 115,000 sh (New)
Chuck Royce 900,000 sh (New)
» More
Q4 2016

NVAX Guru Trades in Q4 2016

Jim Simons 431,415 sh (New)
Chuck Royce 550,000 sh (-38.89%)
Paul Tudor Jones 40,944 sh (-64.40%)
» More
» Details

Insider Trades

Latest Guru Trades with NVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:OXBDF, NAS:CGEN, NAS:PTGX, NAS:VTVT, NAS:STML, NAS:AVXL, NAS:TRVN, OTCPK:SPHRY, OTCPK:RCAR, NAS:MNOV, OTCPK:BCDA, AMEX:MTNB, NAS:CASC, OTCPK:SIGA, NAS:KMDA, NAS:ENZY, NAS:CYAD, NAS:ABEO, OTCPK:PRMCF, NAS:CLSD » details
Traded in other countries:NVV.Germany,
Headquarter Location:USA
Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Novavax is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Ratios

vs
industry
vs
history
PS Ratio 14.56
NVAX's PS Ratio is ranked lower than
65% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. NVAX: 14.56 )
Ranked among companies with meaningful PS Ratio only.
NVAX' s PS Ratio Range Over the Past 10 Years
Min: 6.47  Med: 60 Max: 1903.33
Current: 14.56
6.47
1903.33
EV-to-EBIT -1.61
NVAX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. NVAX: -1.61 )
Ranked among companies with meaningful EV-to-EBIT only.
NVAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -97.9  Med: -7.1 Max: -1
Current: -1.61
-97.9
-1
EV-to-EBITDA -1.66
NVAX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. NVAX: -1.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -68.7  Med: -7.4 Max: 1829.2
Current: -1.66
-68.7
1829.2
Current Ratio 4.33
NVAX's Current Ratio is ranked higher than
52% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. NVAX: 4.33 )
Ranked among companies with meaningful Current Ratio only.
NVAX' s Current Ratio Range Over the Past 10 Years
Min: 0.69  Med: 4.32 Max: 14.49
Current: 4.33
0.69
14.49
Quick Ratio 4.10
NVAX's Quick Ratio is ranked higher than
52% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. NVAX: 4.10 )
Ranked among companies with meaningful Quick Ratio only.
NVAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 4.1 Max: 14.37
Current: 4.1
0.69
14.37
Days Sales Outstanding 5.54
NVAX's Days Sales Outstanding is ranked higher than
92% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. NVAX: 5.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 5.54  Med: 53.15 Max: 289.75
Current: 5.54
5.54
289.75

Buy Back

vs
industry
vs
history
5-Year Yield-on-Cost % 7.00
NVAX's 5-Year Yield-on-Cost % is ranked higher than
87% of the 265 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. NVAX: 7.00 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVAX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 7
3-Year Average Share Buyback Ratio -9.10
NVAX's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. NVAX: -9.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.9  Med: -19.25 Max: -8.1
Current: -9.1
-29.9
-8.1

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.24
NVAX's Price-to-Median-PS-Value is ranked higher than
86% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. NVAX: 0.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.72 Max: 14.78
Current: 0.24
0.07
14.78
Earnings Yield (Greenblatt) % -62.11
NVAX's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. NVAX: -62.11 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -169.5  Med: 0 Max: 0
Current: -62.11
-169.5
0

More Statistics

Revenue (TTM) (Mil) $15.35
EPS (TTM) $ -1.03
Beta2.17
Short Percentage of Float26.22%
52-Week Range $0.73 - 8.49
Shares Outstanding (Mil)271.95

Analyst Estimate

Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.71 -0.59
EPS without NRI ($) -0.71 -0.59
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:NVAX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: United States Steel Corp, Tuesday Morning Corp, Novavax Inc. Feb 08 2015 
Novavax Inc. Reports Operating Results (10-Q) Nov 08 2010 
Novavax Inc. Reports Operating Results (10-Q) Aug 06 2010 
Novavax Inc. Reports Operating Results (10-Q) May 10 2010 
Novavax Inc. Reports Operating Results (10-Q) Nov 09 2009 
Novavax Inc. Reports Operating Results (10-Q) Aug 10 2009 
Novavax Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
ETFs with exposure to Novavax, Inc. : April 19, 2017 Apr 19 2017
Biotech Movers Trading Positive Ahead of Market's Open Apr 11 2017
Down 12.5%: Is Novavax Stock Too Cheap To Ignore? Apr 07 2017
Valeant, DryShips Don’t Escape Thursday’s 52-Week Low Club Apr 06 2017
Today's Research Reports on Biotech Stocks to Watch: Sarepta Therapeutics and Novavax Apr 06 2017
The Waiting Game Crushed Novavax, Inc. in March, Sending Shares Down 15% Apr 05 2017
Implied Volatility Surging for Novavax (NVAX) Stock Options Apr 05 2017
3 Companies That Might Not Live to See 2020 Mar 31 2017
ETFs with exposure to Novavax, Inc. : March 27, 2017 Mar 27 2017
Biotech Industry Continues to Provide Investors with Gains in 2017: Today's Reports on Peregrine... Mar 27 2017
The 6 Most Shorted Nasdaq Stocks Mar 27 2017
3 Beaten-Up Biotech Stocks: Are They Bargains? Mar 21 2017
Novavax, Inc. :NVAX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Trade Volume Can Speak a Lot About Momentum of a Stock Mar 16 2017
Novavax, Inc. :NVAX-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
These 5 Stocks Under $10 Could Ignite Soon Mar 09 2017
These Popular Stocks Could Prove Toxic for Your Portfolio Mar 09 2017
Why Novavax's Shares Marched Higher in February Mar 06 2017
Biotech's Rally in 2017 Gaining Steam After President Trump's Speech: Today's Reports on BioScrip... Mar 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)